270 related articles for article (PubMed ID: 9766345)
1. Economic implications of lipid-lowering trials: current considerations in selecting a statin.
Farmer JA
Am J Cardiol; 1998 Sep; 82(6A):26M-31M. PubMed ID: 9766345
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
3. [When cholesterol lowering drugs should not be too expensive. Statins are especially effective in secondary prevention].
Thomas HP; Kassner U; Steinhagen-Thiessen E
MMW Fortschr Med; 2000 Jul; 142(30):33-4. PubMed ID: 10955017
[No Abstract] [Full Text] [Related]
4. Relation of clinical benefit to metabolic effects in lipid-lowering therapy.
Herd JA
Am J Cardiol; 1998 Sep; 82(6A):22M-25M. PubMed ID: 9766344
[TBL] [Abstract][Full Text] [Related]
5. [Cost effectiveness of lipid lowering therapy].
Wendland G; Klever-Deichert G; Lauterbach K
Herz; 2001 Dec; 26(8):552-60. PubMed ID: 11820158
[TBL] [Abstract][Full Text] [Related]
6. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
Malhotra HS; Goa KL
Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
[TBL] [Abstract][Full Text] [Related]
7. [Effects of statins on coronary artery disease. Review of the recent publications].
Bednarz B
Przegl Lek; 2003; 60(1):27-9. PubMed ID: 12884643
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.
Prosser LA; Stinnett AA; Goldman PA; Williams LW; Hunink MG; Goldman L; Weinstein MC
Ann Intern Med; 2000 May; 132(10):769-79. PubMed ID: 10819699
[TBL] [Abstract][Full Text] [Related]
9. The new National Cholesterol Education Program guidelines: clinical challenges for more widespread therapy of lipids to treat and prevent coronary heart disease.
Eidelman RS; Lamas GA; Hennekens CH
Arch Intern Med; 2002 Oct; 162(18):2033-6. PubMed ID: 12374510
[No Abstract] [Full Text] [Related]
10. [Which statin is more efficient? Concepts and applications in economic evaluation].
García-Altés A; Jovell AJ
Aten Primaria; 2000 Sep; 26(5):333-8. PubMed ID: 11100606
[No Abstract] [Full Text] [Related]
11. Lipid management with statins. The lower the better?
Laufs U; Liao JK; Böhm M
Z Kardiol; 2004 Jan; 93(1):4-9. PubMed ID: 14740235
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular primary prevention: how high should we set the bar?
Prasad V; Vandross A
Arch Intern Med; 2012 Apr; 172(8):656-9; discussion 659. PubMed ID: 22529231
[TBL] [Abstract][Full Text] [Related]
13. [Coronary heart disease prevention. Are there differences in cholesterol synthesis inhibitors?].
Müller-Wieland D; Faust M; Schleifenbaum T; Krone W
MMW Fortschr Med; 2000 Jul; 142(30):26-8. PubMed ID: 10955015
[TBL] [Abstract][Full Text] [Related]
14. Maximizing the cost-effectiveness of lipid-lowering therapy.
Jacobson TA; Schein JR; Williamson A; Ballantyne CM
Arch Intern Med; 1998 Oct; 158(18):1977-89. PubMed ID: 9778197
[TBL] [Abstract][Full Text] [Related]
15. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
Evans M; Roberts A; Davies S; Rees A
Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
[TBL] [Abstract][Full Text] [Related]
16. A clinical focus on statins.
Auer J; Eber B
Curr Opin Investig Drugs; 2001 Mar; 2(3):382-8. PubMed ID: 11575709
[TBL] [Abstract][Full Text] [Related]
17. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia.
Cook JR; Yin D; Alemao E; Drummond M
Pharmacoeconomics; 2004; 22 Suppl 3():37-48. PubMed ID: 15669152
[TBL] [Abstract][Full Text] [Related]
19. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.
Chatzizisis YS; Koskinas KC; Misirli G; Vaklavas C; Hatzitolios A; Giannoglou GD
Drug Saf; 2010 Mar; 33(3):171-87. PubMed ID: 20158283
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of statins in acute coronary syndromes.
Foody JM; Nissen SE
Am J Cardiol; 2001 Aug; 88(4A):31F-5F. PubMed ID: 11520485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
